Immunotherapy in XXXX ( @entity3052 )--a tool for maintaining remission?

@entity1 @entity1778 @entity3052
Twelve trials of adjuvant immunotherapy in @entity1 suffering from @entity3052 have been analyzed and compared to results from experimental studies. The analysis presents evidence suggesting that the immune response to @entity1778 cells exists in a state of balance; this appears to be regulated by the dose of antigen and the state of the cells used to immunize the @entity1 . The injection of high doses of live @entity1778 cells produced a significantly prolonged duration of the first remission in in @entity3052 @entity1 . Immunization with high doses of irradiated and dead cells induced some prolongation of the remission phase and survival time, although the percentage of survivors after 3 years was not increased in these groups as compared to non-immunized @entity1 . Immunization by the same route using a 100-fold lower amount of @entity1778 cells afforded no protection against relapse of the disease during the maintenance phase. A few @entity1 even developed the relapse earlier than did @entity1 treated with chemotherapy alone. Our understanding of the immune responses to malignant cells has increased considerably during the past 2 decades due to various observations. The results obtained with active immunotherapy of the @entity3052 @entity1 during the same period agree well with experience from laboratory studies. Thus the results confirm the potential of an immunological interaction between the @entity1778 cells and the @entity1 . Consequently, it seems likely that the addition of immunotherapy to the treatment of @entity1 with @entity3052 might be effective and the tool for maintaining the phase of remission by up-to-date immunological engineering.
